12:00 AM
 | 
Jun 18, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Syncria albiglutide: Additional Phase III data

Additional data from the open-label, international Phase III Harmony 7 trial in 841 Type II diabetics showed that once-weekly subcutaneous albiglutide met the secondary endpoint of a significantly greater proportion of patients achieving HbA1c <7% at week 32 vs. once-daily 1.8 mg Victoza liraglutide (52% vs. 42%, p=0.0023). Albiglutide also met the secondary endpoint of significantly reducing FPG from baseline to week 32 vs. Victoza (22 vs....

Read the full 321 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >